Launch rilonacept in recurrent pericarditis in the United States
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we expect to launch rilonacept in recurrent pericarditis, pending FDA approval, in the first half of 2021”
What we found
Evidence strength A What the grades mean
FDA approved ARCALYST for recurrent pericarditis in March 2021, and Kiniksa announced commercial availability through Kiniksa in April 2021, before the June 30, 2021 deadline.
-
A Kiniksa Pharmaceuticals, Ltd. 10-K filed 2022-02-24
“announcing the commercial availability of ARCALYST through Kiniksa in April 2021.” ✓ confirmed on the page
-
A Kiniksa Pharmaceuticals, Ltd. 10-K filed 2022-02-24
“In March 2021, the FDA granted approval for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years of age and older” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Commercial launch of rilonacept in recurrent pericarditis
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Low
- Specificity
- Medium
- Conditional
- Yes: if approved by the FDA
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Kiniksa Pharmaceuticals, Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-KNSA-024219 · Corrections policy